Physician profile
Scott Koch
NPI 1144229469
$18,313.75
in general payments reported to CMS, 2019-2025
53 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,683 · 2020: $2,323 · 2021: $3,050 · 2022: $2,544 · 2023: $2,873 · 2024: $2,693 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,592 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,591.80 |
| Education | $121.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,882.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,786.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,529.63 | 2019-2025 | |
| Novo Nordisk INC | $1,513.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,361.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,307.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $673.30 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $657.18 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.18 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $611.64 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $582.55 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $579.08 | 2019-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $557.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $553.10 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $414.68 | 2019-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.